The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock decreased 1.59% or $0.14 during the last trading session, reaching $8.66. About 95,697 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 18, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
The move comes after 8 months negative chart setup for the $310.20 million company. It was reported on Feb, 18 by Barchart.com. We have $7.88 PT which if reached, will make NASDAQ:XBIT worth $27.92 million less.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – GlobeNewswire” on January 29, 2019, also Benzinga.com with their article: “50 Biggest Movers From Yesterday – Benzinga” published on February 06, 2019, Globenewswire.com published: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” on January 23, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” published on January 28, 2019 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut – Benzinga” with publication date: February 07, 2019.
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $310.20 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.